| Chemical & Physical Properties | |
|---|---|
| CAS Number | 130693-82-2 |
| Catalog No. | 2A-9010236 |
| Chinese Name | 盐酸多佐胺 |
| Synonyms | Dorzolamide hydrochloride; Dorzolamide HCl; Dorzolamide; MFCD00884659 |
| Molecular Formula | C10H17ClN2O4S3 |
| Molecular Weight | 360.90 |
| Purity | 98 |
| Density | 1.53 g/cm3 |
| Boiling Point | 575.8ºC at 760 mmHg |
| Melting Point | 283-285ºC |
| Appearance | powder |
| Storage Condition | Refrigerator |
| Application | Dorzolamide (L671152; MK507) hydrochloride is a carbonic anhydrase (CA) inhibitor that can act on glaucoma. |
| HTC | 2935009090 |
| MDL Number | MFCD00884659 |
| SMILES | Cl.CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O |
| InChI | 1S/C10H16N2O4S3.ClH/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16;/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16);1H/t6-,8-;/m0./s1 |
| InChI Key | OSRUSFPMRGDLAG-QMGYSKNISA-N |
| Beilstein/REAXYS | 5896026 |
| NACRES Code | NA.24 |
| UNSPSC | 41116107 |
| MSDS | msds/10236_1_130693_82_2.pdf |
| Bioactivity | Dorzolamide Hcl(L671152 Hcl; MK507 Hcl) is an anti-glaucoma agent, which is a carbonic anhydrase inhibitor.Target: carbonic anhydrase (CA)Dorzolamide hydrochloride is a carbonic anhydrase inhibitor. It is an anti-glaucoma agent, and acts by decreasing the production of aqueous humour [1]. Glaucoma was induced in the right eye of adult Wistar rats by episcleral venous occlusion. One experimental group was administered dorzolamide hydrochloride 2%-timolol 0.5% combination eye drops, while the other experimental group was administered dorzolamide hydrochloride2% eye drops. Control groups had surgery without drug administration. Drug application was initiated either 2 weeks before surgery (Group A), from the day of surgery (Group B), 2 weeks after surgery (Group C), or 4 weeks after surgery (Group D). RGCs were labeled by intratectal Fluorogold injections and counted from flat-mount preparations, and IOP was measured using Tonopen. Both dorzolamide-timolol combination and dorzolamide hydrochloride, when applied topically, significantly reduced IOP and improved RGC densities in experimental eyes when compared to control eyes. Earlier initiation, as well as longer duration of drug application, resulted in higher RGC densities [2].Clinical indications: Glaucoma; Ocular hypertensionFDA Approved Date: 1995Toxicity: Dizziness, headache, shortness of breath, slow heartbeat, severe asthma, cardiac arrest Related Catalog Signaling Pathways >> Metabolic Enzyme/Protease >> Carbonic Anhydrase Research Areas >> Others References [1]. Rankin AJ, et al. Effects of ocular administration of ophthalmic 2% dorzolamide hydrochloride solution on aqueous humor flow rate and intraocular pressure in clinically normal cats. Am J Vet Res. 2012 Jul;73(7):1074-8. [2]. Sarup V, et al. Dorzolamide and timolol saves retinal ganglion cells in glaucomatous adult rats. J Ocul Pharmacol Ther. 2005 Dec;21(6):454-62. Chemical & Physical Properties Density 1.53 g/cm3 Boiling Point 575.8ºC at 760 mmHg Melting Point 283-285ºC Molecular Formula C10H17ClN2O4S3 Molecular Weight 360.90100 Flash Point 302ºC Exact Mass 360.00400 PSA 151.33000 LogP 4.66680 Vapour Pressure 2.93E-13mmHg at 25°C InChIKey OSRUSFPMRGDLAG-QMGYSKNISA-N SMILES CCNC1CC(C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21.Cl Storage condition Refrigerator |
| Use of | Dorzolamide Hcl(L671152 Hcl; MK507 Hcl) is an anti-glaucoma agent, which is a carbonic anhydrase inhibitor.Target: carbonic anhydrase (CA)Dorzolamide hydrochloride is a carbonic anhydrase inhibitor. It is an anti-glaucoma agent, and acts by decreasing the production of aqueous humour [1]. Glaucoma was induced in the right eye of adult Wistar rats by episcleral venous occlusion. One experimental group was administered dorzolamide hydrochloride 2%-timolol 0.5% combination eye drops, while the other experimental group was administered dorzolamide hydrochloride2% eye drops. Control groups had surgery without drug administration. Drug application was initiated either 2 weeks before surgery (Group A), from the day of surgery (Group B), 2 weeks after surgery (Group C), or 4 weeks after surgery (Group D). RGCs were labeled by intratectal Fluorogold injections and counted from flat-mount preparations, and IOP was measured using Tonopen. Both dorzolamide-timolol combination and dorzolamide hydrochloride, when applied topically, significantly reduced IOP and improved RGC densities in experimental eyes when compared to control eyes. Earlier initiation, as well as longer duration of drug application, resulted in higher RGC densities [2].Clinical indications: Glaucoma; Ocular hypertensionFDA Approved Date: 1995Toxicity: Dizziness, headache, shortness of breath, slow heartbeat, severe asthma, cardiac arrest Properties Articles32 Name dorzolamide hydrochloride Synonym More Synonyms Dorzolamide hydrochloride Biological Activity Description Dorzolamide Hcl(L671152 Hcl; MK507 Hcl) is an anti-glaucoma agent, which is a carbonic anhydrase inhibitor.Target: carbonic anhydrase (CA)Dorzolamide hydrochloride is a carbonic anhydrase inhibitor. It is an anti-glaucoma agent, and acts by decreasing the production of aqueous humour [1]. Glaucoma was induced in the right eye of adult Wistar rats by episcleral venous occlusion. One experimental group was administered dorzolamide hydrochloride 2%-timolol 0.5% combination eye drops, while the other experimental group was administered dorzolamide hydrochloride2% eye drops. Control groups had surgery without drug administration. Drug application was initiated either 2 weeks before surgery (Group A), from the day of surgery (Group B), 2 weeks after surgery (Group C), or 4 weeks after surgery (Group D). RGCs were labeled by intratectal Fluorogold injections and counted from flat-mount preparations, and IOP was measured using Tonopen. Both dorzolamide-timolol combination and dorzolamide hydrochloride, when applied topically, significantly reduced IOP and improved RGC densities in experimental eyes when compared to control eyes. Earlier initiation, as well as longer duration of drug application, resulted in higher RGC densities [2].Clinical indications: Glaucoma; Ocular hypertensionFDA Approved Date: 1995Toxicity: Dizziness, headache, shortness of breath, slow heartbeat, severe asthma, cardiac arrest Related Catalog Signaling Pathways >> Metabolic Enzyme/Protease >> Carbonic Anhydrase Research Areas >> Others References [1]. Rankin AJ, et al. Effects of ocular administration of ophthalmic 2% dorzolamide hydrochloride solution on aqueous humor flow rate and intraocular pressure in clinically normal cats. Am J Vet Res. 2012 Jul;73(7):1074-8. [2]. Sarup V, et al. Dorzolamide and timolol saves retinal ganglion cells in glaucomatous adult rats. J Ocul Pharmacol Ther. 2005 Dec;21(6):454-62. Chemical & Physical Properties Exact Mass 360.00400 PSA 151.33000 LogP 4.66680 InChIKey OSRUSFPMRGDLAG-QMGYSKNISA-N Storage condition Refrigerator |
| Tax Rebate | 9.0% |
| Supervision | None MFN tariff: 6.5% Ordinary tariff: 35.0% |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information United Nations classification: inconsistent with United Nations classification standards UN number: not specified |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| Domiphen bromide | 538-71-6 | 2A-9010225 |
| Donaxine;Gramine | 87-52-5 | 2A-9010226 |
| Doramectin | 117704-25-3 | 2A-9010232 |
| Doretinel | 104561-36-6 | 2A-9010233 |
| Dorzolamide | 120279-96-1 | 2A-0200605 |
| Dotarizine | 84625-59-2 | 2A-9010238 |
| Dothiepin hydrochloride | 897-15-4 | 2A-9010239 |
| Doxaminol | 55286-56-1 | 2A-9010240 |
| Doxapram HCl | 7081-53-0 | 2A-9010241 |
| Doxazosin | 74191-85-8 | 2A-9010242 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS